Corona Del Mar, CA, United States of America

Larry Eugene Overman

USPTO Granted Patents = 11 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 27(Granted Patents)

Location History:

Irvine, CA (US) (2017)
Corona Del Mar, CA (US) (1987 - 2023)

Company Filing History:

11 out of 15,458

University of California

where one patent can have more than one assignee

Years Active: 1987-2023

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11584760 - Dithio ETP derivatives (2023-02-21),

2. 11311551 - Use of H3K9me3 modulation for enhancing cognitive function (2022-04-26),

3. 10849910 - Use of H3K9me3 modulation for enhancing cognitive function (2020-12-01),

4. 10822353 - Dithio ETP derivatives (2020-11-03),

5. 10272093 - Use of H3K9me3 modulation for enhancing cognitive function (2019-04-30),

6. 10246471 - ETP derivatives (2019-04-02),

7. 9856273 - ETP derivatives (2018-01-02),

8. 9828342 - Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof (2017-11-28),

9. 9527868 - ETP derivatives (2016-12-27),

10. 5627169 - Selective antagonists for GABA.sub.rho receptor (1997-05-06),

11. 4675325 - Synthesis of indolizidines related to the carditonic pumiliotoxin a (1987-06-23),

Title: Larry Eugene Overman: Innovator in Cancer Treatment and Cognitive Function Enhancement

Introduction

Larry Eugene Overman is a prominent inventor based in Corona Del Mar, California. He holds a total of 11 patents, showcasing his significant contributions to the fields of cancer treatment and cognitive function enhancement. His innovative work has the potential to impact many lives positively.

Latest Patents

Among his latest patents, Overman has developed compositions and methods for the treatment of cancer, specifically focusing on Dithio ETP derivatives. Additionally, he has explored the use of H3K9me3 modulation to enhance cognitive function and treat anxiety-related disorders. This innovative approach involves administering a composition that includes a therapeutically effective amount of a SUV39H1 inhibitor, comprising analogs of ETP69. These advancements aim to address cognitive dysfunction associated with aging and age-related disorders.

Career Highlights

Overman's career has been marked by his association with esteemed institutions such as the University of California and City of Hope. His work in these organizations has allowed him to collaborate with other leading experts in the field, further enhancing his contributions to medical science.

Collaborations

Some of his notable coworkers include David A. Horne and Sangkil Nam. Their collaborative efforts have played a crucial role in advancing the research and development of innovative treatments.

Conclusion

Larry Eugene Overman is a distinguished inventor whose work in cancer treatment and cognitive function enhancement continues to pave the way for future innovations. His dedication to improving health outcomes through scientific research is commendable and impactful.

This text is generated by artificial intelligence and may not be accurate.